Aquestive Therapeutics (AQST) Revenue (2017 - 2026)

Aquestive Therapeutics has reported Revenue for 10 years, with the latest figure at $13.8 million in Q2 2026.

• On a quarterly basis, Revenue rose 38.15% year-over-year to $13.8 million in Q2 2026; TTM through Jun 2026 was $54.1 million, a 22.56% increase from a year earlier, with the FY2025 full-year figure at $44.5 million, down 22.61% from the prior year.
• Revenue was $13.8 million for Q2 2026 at Aquestive Therapeutics, down from $14.4 million in the prior quarter.
• The five-year high for Revenue was $20.1 million in Q2 2024, with the low at $8.7 million in Q1 2025.
• Average Revenue over 5 years is $12.7 million, with a median of $12.9 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Revenue sank 50.23% in 2025, then surged 65.67% in 2026.
• Over 5 years, Revenue stood at $10.7 million in 2022, then rose by 23.63% to $13.2 million in 2023, then retreated by 10.14% to $11.9 million in 2024, then rose by 9.67% to $13.0 million in 2025, then increased by 6.18% to $13.8 million in 2026.
• The last three Revenue figures came in at $13.8 million (Q2 2026), $14.4 million (Q1 2026), and $13.0 million (Q4 2025), per Business Quant data.